News

May 29, 2020May 29, 2020

Benlysta Treatment Lowers Disease Activity for SLE Patients, Real-world Data Shows

News

Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a significant proportion of patients achieve durable remission or a status of ... Read more

May 22, 2020May 22, 2020

Global Registry Studying COVID-19 Impact on Lupus, Other Rheumatic Diseases

News

Rheumatologists, researchers, and patients have joined forces on a global scale to better understand how COVID-19 affects people with rheumatic diseases, including those with systemic lupus erythematosus (SLE). The ... Read more

May 15, 2020May 15, 2020

Global Survey Finds Lupus Greatly Affects Physical Function and Life Quality

News

Lupus significantly affects mobility and the ability to conduct everyday activities, according to a global World Lupus Federation survey. Results of the questionnaire, which surveyed more than 4,000 people ... Read more

May 8, 2020May 8, 2020

Lupus Awareness Month Marked by Local, Online and Worldwide Activities

News

Despite the COVID-19 outbreak, ample online ways exist to mark Lupus Awareness Month, observed each May to call attention to lupus and raise funds for research and education. The ... Read more

April 27, 2020April 28, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in ... Read more

April 24, 2020April 24, 2020

Study of Hydroxychloroquine vs. COVID-19 Planned for SLE Patients

News

Lupus Therapeutics, an affiliate of the Lupus Research Alliance (LRA), announced that it is working to design and run a clinical trial into whether hydroxychloroquine and other therapies for systemic lupus erythematosus (SLE) ... Read more

April 17, 2020April 17, 2020

RC18 Receives FDA’s Fast Track Designation for Treating SLE

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on the FDA’s fast ... Read more

April 10, 2020April 10, 2020

RemeGen Raises $100M to Advance Potential Lupus Treatment, RC18

News

RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical ... Read more

April 3, 2020April 3, 2020

Phase 3 Results Suggest Low-Dose Prednisone Lowers Flare Risk in SLE Patients in Remission

News

People with systemic lupus erythematosus (SLE) who have been in remission for at least a year and take low-dose prednisone as maintenance therapy have less risk of a disease ... Read more

March 27, 2020March 27, 2020

Voclosporin Helps Protect Kidneys in Lupus Nephritis, Phase 3 Trial Shows

News

Adding the experimental oral therapy voclosporin to standard treatment is safe, and its use more than doubles complete kidney responses in people with lupus nephritis, results from the Phase 3 ... Read more